CDR-Life Inc. has reported preclinical data for the CDR-813, a novel antibody fragment-based bivalent T-cell engager targeting preferentially expressed antigen in melanoma (PRAME) on HLA-A*02:01.
Video: Medium- or High-Potency Steroids for Atopic Dermatitis? —Although data show similar results for both, sometimes high-potency steroids are necesarry. Megan Rogge, MD, of McGovern Medical ...